Chemical Tag on mRNA Emerges as Master Switch Behind Tumor Immune Evasion

Deep inside every tumor cell, a microscopic chemical tag is quietly deciding whether the immune system sees the cancer or ignores it. That tag, known as N⁶-methyladenosine, or m⁶A, is the most abundant modification found on messenger RNA in mammalian cells, and according to a comprehensive new review published in the Journal of Translational Medicine, it sits at the very center of the tug-of-war between cancer and innate immunity. The review, led by Lan Chen and Yuanyuan Zhu of Harbin Medical University together with Xi Liu of Ordos Central Hospital, synthesizes a rapidly expanding body of evidence showing that m⁶A does not merely fine-tune gene expression. Instead, it acts as a pivotal epitranscriptomic hub that integrates oncogenic signals, metabolic states, and cues from the tumor microenvironment, ultimately determining whether innate immune pathways fire against the tumor or fall silent.

To understand why this matters, it helps to grasp the mechanics of the modification itself. m⁶A is deposited on adenosine bases within mRNA by a set of enzymes collectively called writers, the best characterized of which is the methyltransferase complex built around METTL3. Those marks can then be removed by erasers, chiefly the demethylases FTO and ALKBH5, and interpreted by readers, most notably proteins of the YTH domain family such as YTHDF1, that dictate whether a given transcript is stabilized, degraded, exported, or translated. Through this Writers–Erasers–Readers network, a cell can rapidly reprogram its entire protein output without changing a single letter of DNA sequence. The review emphasizes that this system is exquisitely sensitive to the conditions inside a tumor, responding to inflammatory signals, hypoxia, and metabolic stress, and that its output can swing the immune response in either direction.

The first direction is the one oncologists want: amplification of anti-tumor immunity. When the m⁶A machinery is configured favorably, it promotes type I interferon signaling, the chemical alarm system that alerts neighboring cells to danger. It also supports the maturation of dendritic cells, the sentinels that capture tumor antigens and present them to T cells, and it enhances antigen presentation itself, making cancer cells more visible to immune surveillance. The review highlights that reader proteins such as YTHDF1 can boost the translation of immune-related transcripts, while proper m⁶A deposition encourages macrophages to polarize toward the M1-like state, the pro-inflammatory, tumor-killing flavor of these scavenger cells. In these settings, m⁶A effectively turns up the volume on the innate immune system, priming the adaptive response that immune checkpoint blockade therapies are designed to unleash.

The second direction is far darker. Tumors have learned to hijack the very same machinery for their own protection. The review documents how cancer cells manipulate m⁶A regulators to suppress the cGAS-STING pathway, the intracellular sensor that normally detects leaked tumor DNA and triggers interferon production. They also dampen RIG-I and MDA5, the cytoplasmic receptors that recognize viral-like double-stranded RNA, and they promote the degradation of antigen transcripts, effectively erasing the molecular fingerprints that would otherwise expose them to cytotoxic T cells. Perhaps most strikingly, tumor-hijacked m⁶A enzymes silence viral mimicry, the process by which endogenous retroviruses and other repetitive elements in the genome are reactivated to produce double-stranded RNAs that fool the cell into thinking it is infected. When that ancient alarm is muffled, tumors shed one of their most potent endogenous triggers of immune attack.

The consequences ripple outward into the tumor immune microenvironment. The review describes how altered m⁶A signaling skews macrophage polarization away from the M1 state and toward the M2 phenotype, which suppresses inflammation and supports tumor growth. It also drives what the authors call immunosuppressive myeloid remodeling, expanding populations of myeloid-derived suppressor cells and other innate cells that actively paralyze T cells. In parallel, m⁶A regulation extends into non-coding RNA networks, including competing endogenous RNA circuits, that modulate how much interferon and inflammatory signaling a tumor cell generates. The net effect is a microenvironment in which the innate arm of immunity, which should be the first line of defense, has been co-opted into an accomplice of the cancer.

This mechanistic picture leads the authors to a conceptual proposal that may prove to be the review’s most influential contribution: an m⁶A-driven immunophenotyping framework. Rather than treating all tumors as a single immunological entity, the framework stratifies cancers into three mechanistically distinct categories. The first comprises dendritic cell-dysfunctional so-called cold tumors, in which antigen presentation and T cell priming fail at the very first step. The second consists of innate-sensing-silent tumors, in which cGAS-STING and RIG-I/MDA5 pathways have been shut down so that no interferon alarm sounds even when tumor DNA and RNA are abundant. The third encompasses myeloid-suppressed hot tumors, which may look inflamed on paper but are flooded with suppressive myeloid cells that neutralize any T cell response that does arise. Each category, the authors argue, reflects a different pattern of m⁶A dysregulation and therefore demands a different therapeutic approach.

The therapeutic implications are concrete. For tumors in which the reader protein YTHDF1 drives immune evasion, inhibiting that reader could restore antigen presentation and dendritic cell function. For tumors relying on the erasers FTO or ALKBH5 to keep interferon signaling suppressed, pharmacological demethylase inhibition could reactivate viral mimicry and innate sensing, converting a cold tumor into a hot one. Conversely, in contexts where METTL3 activity itself fuels immunosuppressive myeloid remodeling, blocking the writer becomes the rational move. The review stresses that these interventions should be phenotype-specific and guided by precise biomarkers, since applying the wrong m⁶A-targeting strategy to the wrong tumor type could plausibly worsen immune suppression rather than relieve it. This mechanism-based stratification, the authors suggest, offers a path to overcoming the resistance that so frequently defeats T cell-centered immune checkpoint blockade.

That resistance problem is the clinical backdrop against which the entire review is written. Immune checkpoint inhibitors have transformed outcomes in melanoma, lung cancer, and several other malignancies, yet a large fraction of patients either never respond or relapse after an initial benefit. The review’s framing of innate immunity as a double-edged sword helps explain why: the same pathways that suppress tumorigenesis early can, under chronic inflammatory conditions, sculpt an immunosuppressive microenvironment that shields the tumor from T cells. Because m⁶A regulates both faces of that sword, it represents a uniquely powerful lever. Modulating it does not simply add another drug to the arsenal; it potentially reprograms the fundamental immunological character of the tumor, shifting the balance from suppression to activation.

Significant obstacles remain before this vision reaches the clinic. The review is candid that tumor-selective delivery of m⁶A-targeting agents is an unsolved problem, since the Writers–Erasers–Readers network operates in every cell of the body and indiscriminate interference could unleash inflammatory toxicity or impair normal immune function. Safety evaluation will need to establish that manipulating m⁶A in tumors does not destabilize the delicate equilibrium of innate immunity elsewhere. Biomarker development is equally critical, because the proposed phenotyping framework depends on reliably identifying which m⁶A-driven state a given patient’s tumor occupies, likely through transcriptomic signatures and computational methods of the kind the field has begun to apply.

Even so, the synthesis offered by Chen, Zhu, Liu, and their colleagues marks a shift in how scientists think about the interface between RNA chemistry and cancer immunology. A modification once studied as a curiosity of mRNA metabolism now emerges as a master regulator of innate immune signaling, a sculptor of the tumor microenvironment, and a plausible explanation for why some tumors hide in plain sight from the immune system. If the framework holds up under experimental and clinical scrutiny, the humble methyl group on adenosine may become one of the most consequential targets in the next generation of cancer immunotherapy, turning the epitranscriptome from a subject of basic research into a battlefield where the war against immune-resistant tumors is fought.

Subject of Research: m6A RNA modification regulation of innate immune signaling and the tumor immune microenvironment

Article Title: N⁶-methyladenosine modification regulates innate immune signaling and reshapes the tumor immune microenvironment: a review

Article References: Chen, L., Wang, Y., Zhang, M., Shen, Y., Li, J., Hu, X., Fan, Z., Zhang, Y., Qin, Y., Zhu, Y., & Liu, X. (2026). N⁶-methyladenosine modification regulates innate immune signaling and reshapes the tumor immune microenvironment: a review. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09045-6

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09045-6

Keywords: m6A modification, epitranscriptomics, innate immunity, cGAS-STING, RIG-I, tumor immune microenvironment, immune checkpoint blockade, dendritic cells, macrophage polarization, viral mimicry, YTHDF1, FTO